Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Biosimilars Rise Is Cold Comfort For Biogen As Tecfidera Competition Bites
Signals ‘Financial Reset’ In 2021 Due To Dimethyl Fumarate Generics
Feb 04 2021
•
By
David Wallace
Biogen expects a ‘reset’ in 2021 due to Tecfidera generics • Source: Shutterstock
More from Earnings
More from Business
